Have you or your loved ones been diagnosed with acquired immune deficiency syndrome (aids)?

You may be eligible to participate in a acquired immune deficiency syndrome (aids) clinical trial.

Have you or your loved ones been diagnosed with acquired immune deficiency syndrome (aids)? You may be eligible to participate in a acquired immune deficiency syndrome (aids) clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Acquired Immune Deficiency Syndrome (AIDS) Clinical Trial
NCT01854775 | Phase 2 phase 3 | Interventional
Gilead Sciences
Sponsored by
Gilead Sciences

Have you or your loved ones been diagnosed with acquired immune deficiency syndrome (aids)?

You may be eligible to participate in a acquired immune deficiency syndrome (aids) clinical trial.

Have you or your loved ones been diagnosed with acquired immune deficiency syndrome (aids)? You may be eligible to participate in a acquired immune deficiency syndrome (aids) clinical trial.

Active not recruiting

Male & Female

2 - 17

Years old

This study has recruited 129 Participants

The primary objectives of Cohort 1 are to evaluate the steady state pharmacokinetics (PK) for elvitegravir (EVG) and tenofovir alafenamide (TAF) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through Week 24 (Part B) in human immunodeficiency virus - 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive adolescents. The primary objectives of Cohort 2 are to evaluate the PK of EVG and TAF in virologically suppressed HIV-1 infected children 6 to < 12 years of age weighing ≥ 25 kg administered E/C/F/TAF STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through Week 24 in virologically suppressed HIV-1 infected children 6 to < 12 years of age weighing ≥ 25 kg (Part B). The primary objectives of Cohort 3 are to evaluate the PK of EVG and TAF and confirm the dose of the STR, and to evaluate the safety and tolerability of E/C/F/TAF low dose (LD) STR in virologically suppressed HIV-1 infected children ≥ 2 years of age and weighing ≥ 14 to < 25 kg.